Leading UK medical journal The Lancet on March 9 said that indigenously developed Covaxin was found to be safe & has demonstrated better performance in the Phase 2 trials compared to Phase 1. The report said that the vaccine developed by Hyderabad-based Bharat Biotech showed better reactogenicity & safety outcomes & enhanced humoral & cell-mediated immune responses compared with the Phase 1 trials. It comes just days after Bharat Biotech and Indian Council of Medical Research (ICMR) announced that Covaxin demonstrated nearly 81% efficacy in interim Phase 3 trials. The paper said that the most common adverse event in the phase 2 trial was pain at the injection site, followed by headache, fatigue, and fever. Watch the video to know more.
